Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceGut health

Clostridium Butyricum

A spore-forming probiotic that produces butyrate in the colon, used mainly in Japan and China. One reasonably sized trial in diarrhoea-predominant IBS is positive, but the overall human evidence base is thin.

Evidence last reviewed: August 2026

What the science says

  • Diarrhoea-predominant IBS symptoms Limited evidence

    A multicentre, double-blind, placebo-controlled trial in 200 patients with IBS-D found modest improvements in overall symptom score, stool frequency and quality of life over 4 weeks, with a responder rate of 45% versus 31% on placebo. It is a single trial and the absolute differences were small.

  • Colorectal adenoma recurrence Limited evidence

    A randomised crossover trial in 398 patients with a history of adenomatous polyps found lower polyp counts and recurrence with CBM588, but only in the per-protocol analysis; the intention-to-treat comparison was not statistically significant.

  • General gut health and butyrate production Limited evidence

    The rationale is that the strain produces butyrate, the main fuel for colonocytes, but no trial has shown that supplementing this species improves a hard clinical outcome in healthy people.

Dosage & safety

Studied doseTrials used commercial preparations (CBM588 / MIYAIRI 588) taken three times daily with meals, for 4 weeks up to 2 years. Typical label doses are in the range of 10^7–10^8 CFU per day.
SafetyWell tolerated in trials, with no serious adverse events reported. As with any live probiotic, people who are severely immunocompromised, have central venous catheters or are critically ill should avoid it unless a doctor advises otherwise.

Scientific references

Where to buy

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Gut health